Safety evaluation of aqueous extracts of Sanghuangporus vaninii fruiting body in Sprague–Dawley rats

Abstract

Sanghuangporus vaninii, called “Sanghuang,” is orally used for health care, tumor, and inflammation treatment in Asia. However, the safety of S. vaninii has not been evaluated. The major compounds analysis showed that aqueous extracts of S. vaninii fruiting body were rich in polysaccharides, nucleotides, and polyphenols. Then, the aqueous was given orally to Sprague–Dawley rats for toxical test. In acute toxicity study, the maximum tolerated dose was 21 g/kg. In 17‐week repeated dose toxicity experiment, all rats had no abnormal reaction among control group, low dose group (0.15 g/kg) and middle dose group (1.00 g/kg). At high dose group (6.00 g/kg), the feces began to darken on 16th day (D16), and turned to drug stained stool on D21, all rats recovered on the 3rd day (D92) of recovery period. During the whole experiment, there were no animal death and no treatment‐related changes in any of the parameters under the all doses. These results indicated the No‐Observed Adverse Effect Level of aqueous extract of S. vaninii fruiting body was 1.0 g/kg.

Aqueous extracts of Sanghuangporus vaninii induce S‑phase arrest and apoptosis in human melanoma A375 cells

“…The content of total polysaccharides and polyphenols was 5.51 and 23.00%, respectively. The major polyphenols were 3,4-dihydroxybenzalacetone, phellibaumin D and interfungin B ( 17 ).…”

Sanghuangporus vaninii extract ameliorates hyperlipidemia in rats by mechanisms identified with transcriptome analysis

“…For this reason, pharmaceutical research has concentrated to identify effective lipid-lowering drugs which preferably have few side effects. S. vaninii is an edible and medicinal mushroom with various efficacy (Guo et al, 2021); its safety and its potential to reduce blood lipid levels make it a likely antihyperlipidemia agent Huo et al, 2020).…”

“…For this reason, pharmaceutical research has concentrated to identify effective lipid‐lowering drugs which preferably have few side effects. S. vaninii is an edible and medicinal mushroom with various efficacy (Guo et al., 2021 ); its safety and its potential to reduce blood lipid levels make it a likely anti‐hyperlipidemia agent (Huang, Liu, et al., 2022 ; Huo et al., 2020 ). In this study, a high‐fat diet was used to induce hyperlipidemia in rats, who were then treated with SVE to confirm the effects of S. vaninii , with simvastatin as a positive control.…”

Current advances and potential trends of the polysaccharides derived from medicinal mushrooms sanghuang

“…Previous studies have validated that the administration of sanghuang extracts seems to be non-toxic or hypotoxic (Huo et al, 2020 ; Li I. C. et al, 2020 ). For efficient uses in nutraceuticals, pharmaceuticals, and cosmeceuticals, the assessment of safety, adverse effects, and efficacies of sanghuang polysaccharides is imminently necessitated in deciding the normative dosage and administration duration in the next steps, such as acute oral toxicity test, chromosome aberration test, bone marrow micronucleus test, and clinical test.…”